siRNA-mediated gene silencing in vitro and in vivo

By Haibin Xia, Q. Mao, H. Paulson, B. Davidson. Nature Biotechnology, 2002

921 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Genetics, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/c828f0aa98acf5e3183ffef43ec9d08a8b672a68

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

In Genetics

In Molecular Biology

Citations in the corpus

RNA interference targeting Fas protects mice from fulminant hepatitis (2003, background): “Viral-mediated delivery of siRNA in vivo reduces exogenous green fluorescent protein (GFP) and endogenous glucuronidase expressio”
Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: Implications for the therapeutic development of RNAi (2008, background): “Conversely, shRNAs have limited spacing flexibility for expressing shRNAs from Pol-II-based promoters (16).”
Activation of the interferon system by short-interfering RNAs (2003, methodology): “One technique of expressing the short double-stranded (ds) RNA intermediates required for interference in mammalian systems is the introduction of short-interfering (si) RNA”
RNAi therapeutics: principles, prospects and challenges. (2007, background): “One important problem with this is that shRNAs need to initiate with the first base of the shRNA for proper processing and work best when the shRNA is followed by a minimal, rather than a complete poly A signal [39].”
Progress and problems with the use of viral vectors for gene therapy (2003, methodology): “RNAi technology has already been incorporated into adenoviru”
Lentivirus-delivered stable gene silencing by RNAi in primary cells. (2003, background): “Moreover, preexisting immunity to adenoviral vectors (Yang et al. 1994) potentially limits their use in vivo.”
Current prospects for RNA interference-based therapies (2011, background): “One of the first organs tested for the effectiveness of RNAi in vivo was the liver 127, 128 , and RNAi-based treatments for metabolic diseases (such as hypercholesterolaemia), viral infections, cancer 6 and liver fibrosis (reviewed in REF. 129 ) are in progress.”
Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. (2005, background): “Therefore, most studies using siRNA in vivo involve manipulation of gene expression in a cell line before introduction into an animal model (6, 7) or incorporation of siRNA into a viral vector ( 8 , 9). Delivery of ‘‘naked’’ siRNA in vivo has been restricted to site-specific injections or through hi”